Search results
Wednesday 28 January 2026, 7.00pm - 8.00pm - via Zoom - Come and join us for our first meeting of the year where our host Mark Baxter will be sharing some information from the Visionary panel session - 'Unlocking the Potential of A.I Wearable Technology'.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Volunteers are highly valued members of the Retina UK team and essential to our ability to achieve our vision of a world where all those affected by inherited retinal conditions are able to live a fulfilling life.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
